Skip to Content

Baxter International Inc

BAX: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$72.00DwdnxxWgkxwnlg

Baxter Earnings: Mildly Exceeds Cautious Expectations on Improving Medical Utilization

Narrow-moat Baxter mildly exceeded expectations in the third quarter, and management largely maintained its 2023 outlook. Our near-term estimates remain roughly in line with these expectations, and we are keeping our $67 fair value estimate intact, well above recent trades.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BAX so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center